- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02553668
Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression
Aim of the present study is to investigate the influence of hyperoxia on the protein expression using the differential analysis of protein expression in tissues (proteomics). In the study, blood and urine samples will be collected from participants who undergo a short term hyperoxia using 100% oxgen for 3 hours.
Here, gel electrophoresis, protein separation and mass spectroscopy allow to identify affected proteins. Based on these results, different induction factors of proteins will be determined and then assessed using a bioinformatic network analysis regarding the cellular influence.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oxygen is necessary to sustain human life and is used for energy production by oxidation in the mitochondria. Application of oxygen not only increases saturation in the patient's blood, but also has various secondary effects. It is therefore used to treat diseases that impairs body's ability to take up and use oxygen. But even healthy people can suffer from hypoxia when they ascend to high altitude. Here, altitude sickness can lead to potentially fatal complications such as high altitude cerebral edema or high altitude pulmonary edema. Since hypoxia can have disastrous consequences, hyperoxia is often tolerated in many pre- and in-hospital situations.
Whereas the effects of hypoxia are well studied, especially publications in the last decade have led to a new perspective on oxygen application. Besides pathophysiological changes as the peripheral vasoconstriction or reduction of contractility, especially changes on cellular level seem to be of great importance. Here, oxidative stress and change of protein synthesis in various organ are focus of current studies.
The differential analysis of protein expression in tissues (proteomics) is an important approach for better understanding of the negative effects of hyperoxia. Especially for patients with long-term high oxygen demand the knowledge of cellular changes during hyperoxia can result in new therapeutic approaches and a reduction in the rate of complications.
In the present molecular biology study urine and blood samples of healthy volunteers will be collected at specified times after short-term exposure to oxygen. These samples will be analyzed after the study using the differential analysis of protein expression. The aim of this study is to investigate the effects of oxygen on the cell functions by analyzing and subsequent bioinformatic processing of differentially regulated proteins in the blood and urine.
After checking the inclusion and exclusion criteria biometric data of the test persons are collected.
Before short-term hyperoxia a sample collection of blood and urine will be performed. Here the participants are taken 5 ml of venous blood from the cephalic vein under sterile conditions. To obtain the urine sample spontaneous urine of participants is used. The samples are immediately centrifuged and flash frozen at -80°C. In order to exclude impairment of the lung prior to the short-term hyperoxia a pulmonary function test is carried out by using a hand spirometer.
To induce hyperoxia subjects inhale 100% oxygen for 3 hours through a face mask.
After carrying out the short term hyperoxia the follow up phase takes place. In this phase blood and urine samples from the subjects will be obtained directly after the hyperoxia (T0), on day 1 (T1), day 3 (T3), day 7 (T7), day 14 (T14), day 21 (T21) and day 28 (T28) after oxygen exposure. All samples will be centrifuged immediately after collection and flash frozen at -80 ° C. To exclude hyperoxia-induced lung impairments, a spirometry is performed during the follow up.
After the samples of all subjects were collected the analysis of the samples will be carried out using Proteomics.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) 1
- >18 years
- < 50 years
Exclusion Criteria:
- American Society of Anesthesiologists (ASA) > 1
- pregnant
- <18 years
- > 50 years
- frequent or recent drug intake
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Hyperoxia
Participants receive 100% oxygen
|
Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of proteomics changes before and after short-term hyperoxia
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spirometry Results: Forced vital capacity (FVC) [L]
Time Frame: 2 days
|
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
|
2 days
|
|
Spirometry Results: Forced expiratory volume at one second (FEV1) [L]
Time Frame: 2 days
|
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
|
2 days
|
|
Spirometry Results: Forced expiratory flow (FEF25-75) [L/s]
Time Frame: 2 days
|
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
|
2 days
|
|
Spirometry Results: Peak expiratory flow (PEF) [L/s]
Time Frame: 2 days
|
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
|
2 days
|
|
Vital parameter: Respiratory rate (RR) [1/min]
Time Frame: 3 hours
|
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
|
3 hours
|
|
Vital parameter: Heart rate (HR) [1/min]
Time Frame: 3 hours
|
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
|
3 hours
|
|
Vital parameter: Blood pressure (BP) [mmHg]
Time Frame: 3 hours
|
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
|
3 hours
|
|
Vital parameter: Oxygen saturation (SpO2) [%]
Time Frame: 3 hours
|
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
|
3 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stefan Braunecker, M.D., Universityhospital of Cologne
Publications and helpful links
General Publications
- Spelten O, Wetsch WA, Wrettos G, Kalenka A, Hinkelbein J. Response of rat lung tissue to short-term hyperoxia: a proteomic approach. Mol Cell Biochem. 2013 Nov;383(1-2):231-42. doi: 10.1007/s11010-013-1771-y. Epub 2013 Aug 11.
- Hinkelbein J, Feldmann RE Jr, Kalenka A. Time-dependent alterations of cerebral proteins following short-term normobaric hyperoxia. Mol Cell Biochem. 2010 Jun;339(1-2):9-21. doi: 10.1007/s11010-009-0365-1. Epub 2010 Jan 5.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperoxia
-
Northern State Medical UniversityCompletedHypocapnia | Response to HyperoxiaRussian Federation
-
Istanbul UniversityCompleted
-
Copenhagen University Hospital, HvidovreThe Ludvig & Sara Elsass FoundationCompletedResponse to HyperoxiaDenmark
-
Istinye UniversityNot yet recruitingHyperoxia / High FiO₂ Exposure | Uric Acid/Albumin Ratio (UAR)
-
Haute Ecole Bruxelles-BrabantCompletedHigh Intensity Interval Training | Hypoxia | Interval Training | VO2max | HIIT | Hyperoxia / High FiO₂ ExposureBelgium
-
Masimo CorporationCompleted
-
Zonguldak Bulent Ecevit UniversityCompleted
-
SIZ NursingCompleted
-
University of Missouri-ColumbiaSacred Heart Health SystemCompleted
Clinical Trials on Oxygen (FiO2 1,0)
-
Yale UniversityWithdrawn
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalCompletedCardiac Output
-
Hennepin Healthcare Research InstituteCompletedTraumatic Brain InjuryUnited States
-
Beth Israel Deaconess Medical CenterCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Centre Hospitalier Universitaire de BesançonUnknownAcute Respiratory Distress Syndrome | Intensive CareFrance
-
Centre Hospitalier Universitaire de BesançonUnknownAcute Respiratory Distress SyndromeFrance
-
Saint Thomas Hospital, PanamaCompletedSurgical Wound InfectionPanama
-
Tepecik Training and Research HospitalCompletedComplication | Mechanical Ventilation Complication | HyperoxiaTurkey